Epigenetics and chromatin biology
5 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- INSTITUT CURIE
Leading French cancer research centre combining clinical oncology with fundamental epigenetics, genomics, and cell biology across 83 H2020 projects.
“Deep specialization shown through ChromADICT (histone chaperones), CHROMATIX (X-chromosome inactivation), EPOCH28 (epigenetic profiling), and Drug-Seq (genomic targets of drugs).”
PrimaryFR83 projects - DIAGENODE
Belgian biotech SME providing epigenetics tools, chromatin analysis, and bioinformatics services for genomics research in health and agriculture.
“Core contributor to Chromatin3D, EpiSyStem, ChromDesign, and PEP-NET — all focused on chromatin structure, histone modifications, and epigenetic regulation.”
PrimarySMEBE7 projects - CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS STIFTUNG
Frankfurt cancer research institute specializing in blood malignancies, epigenetic regulation, cancer cell plasticity, and open-science drug target discovery.
“INTERCEPT-MDS explicitly targets epigenetic regulation and chromatin remodeling; PLASTICAN addresses cell plasticity which involves epigenetic reprogramming.”
DE4 projects - IZMIR BIYOTIP VE GENOM MERKEZI
Turkish genome research centre specializing in rare disease genomics, epigenetics, and biomedical technologies, rapidly building EU research capacity.
“RareBoost keywords explicitly include epigenetics, chromatin structure and function, and protein complexes as core research areas.”
PrimaryTR3 projects - KADIMASTEM LTD
Israeli biotech SME developing iPSC-based therapies, with expertise in cardiac regeneration and epigenetic reprogramming mechanisms.
“EpiSyStem's keyword set — epigenetics, chromatin, nucleosome, histone, methylation — indicates participation in mechanistic research underpinning their therapeutic programmes.”
SMEIL2 projects